PMID- 10388046
OWN - NLM
STAT- Publisher
LR  - 20191120
IS  - 1549-490X (Electronic)
IS  - 1083-7159 (Linking)
VI  - 2
IP  - 3
DP  - 1997
TI  - Anti-Leukemia Chemotherapy of High-Risk Myelodysplastic Syndromes.
PG  - 160-163
AB  - We evaluated the outcome of anti-leukemia chemotherapy on 42 patients with the 
      high-risk myelodysplastic syndromes (MDS)-refractory anemia with excess of blasts 
      (RAEB), 8 cases; RAEB in transformation (RAEB-T), 18 cases; chronic 
      myelomonocytic leukemia (CMMOL), 6 cases; and leukemic transformation of MDS, 10 
      cases. The median age was 67 (range 20 to 84). As a remission-induction therapy, 
      35 patients received low-dose chemotherapy, such as low-dose cytarabine infusion, 
      and seven patients received high-dose combination chemotherapy. The complete 
      remission (CR) rates of the low-dose chemotherapy group and the high-dose 
      combination chemotherapy group were 29% and 57%, respectively, and the overall CR 
      rate was 33%. The median survival durations after induction chemotherapy of the 
      CR group (14 cases), the partial remission (PR) group (11 cases), and 
      non-remission (NR) group (17 cases) were 19 months, 8 months, and 3 months, 
      respectively. As a post-remission consolidation chemotherapy, high-dose 
      combination chemotherapy seemed to be superior to low-dose chemotherapy judging 
      from the median CR duration (16 months versus 4 months), but a long-term 
      disease-free survival is hardly expected, in contrast with results in cases of de 
      novo acute myeloid leukemia.
FAU - Tohyama, K
AU  - Tohyama K
AD  - Division of Hematology/Oncology, Graduate School of Medicine, Kyoto University, 
      Kyoto 606-01, Japan.
FAU - Tsutani, H
AU  - Tsutani H
FAU - Wano, Y
AU  - Wano Y
FAU - Iwasaki, H
AU  - Iwasaki H
FAU - Fukushima, T
AU  - Fukushima T
FAU - Urasaki, Y
AU  - Urasaki Y
FAU - Kawai, Y
AU  - Kawai Y
FAU - Nakamura, T
AU  - Nakamura T
FAU - Yoshida, Y
AU  - Yoshida Y
FAU - Ueda, T
AU  - Ueda T
LA  - eng
PT  - Journal Article
PL  - England
TA  - Oncologist
JT  - The oncologist
JID - 9607837
EDAT- 1997/01/01 00:00
MHDA- 1999/07/01 00:00
CRDT- 1997/01/01 00:00
PHST- 1997/01/01 00:00 [pubmed]
PHST- 1999/07/01 00:00 [medline]
PHST- 1997/01/01 00:00 [entrez]
PST - ppublish
SO  - Oncologist. 1997;2(3):160-163.